Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Payables (2016 - 2025)

Fennec Pharmaceuticals' Payables history spans 15 years, with the latest figure at $4.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 43.01% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Dec 2025, up 43.01%, and an annual FY2025 reading of $4.6 million, up 43.01% over the prior year.
  • Payables for Q4 2025 was $4.6 million at Fennec Pharmaceuticals, down from $5.9 million in the prior quarter.
  • The five-year high for Payables was $5.9 million in Q2 2025, with the low at $677000.0 in Q2 2021.
  • Average Payables over 5 years is $3.3 million, with a median of $3.0 million recorded in 2023.
  • Year-over-year, Payables crashed 75.43% in 2021 and then skyrocketed 157.46% in 2022.
  • Tracing FENC's Payables over 5 years: stood at $1.2 million in 2021, then soared by 107.11% to $2.4 million in 2022, then skyrocketed by 58.08% to $3.8 million in 2023, then dropped by 14.21% to $3.2 million in 2024, then soared by 43.01% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Payables are $4.6 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025).